(VCBeat) Aug. 06, 2021 -- Beijing Kangle Weishi Biotechnology Co., Ltd. ("Kangle Weishi") announced the completion of pre-IPO round financing, raising 1.015 billion yuan. The main investors include CCB International, YF Capital, Jemincare, Yingke PE, and other well-known investment institutions in the industry. WinX Capital and Ek Capital acted as co-financial advisors in the latest round.

Proceeds from this round will be mainly used for the clinical researches of Kangle Weishi's trivalent HPV 16/18/58 recombinant vaccine and 9-valent recombinant HPV 6/11/16/18/31/33/45/52/58 vaccine, as well as the construction of the vaccine industrial base in Kunming, the preclinical and recombinant norovirus vaccines, recombinant coronavirus vaccines, and the preclinical studies of other products in development.

In 2015, 2019 and 2020, Kangle Weishi completed three oversubscribed financing, raising 30 million yuan, 50.71 million yuan and 650 million yuan respectively. The successful completion of this financing is mainly due to the steady development of the company's main business, especially the trivalent HPV and nine-valent HPV vaccines have entered the phase III clinical trial.

Founded in 2008, Kangle Weishi mainly develops recombinant protein drugs based on the structural design. The company has gradually established several key technology platforms at home and abroad for recombinant viral-like particle (VLP) vaccine design, VLP protein expression and vaccine engineering technology, VLP vaccine quality evaluation, vaccine antibody preparation, and detection, etc. It has also built up the GMP-compliant pilot base.

CCB International (Holdings) Limited and its subsidiaries ("CCB International") is a financial and investment services company owned by China Construction Bank Corporation ("CCB"). The core business of its subsidiaries comprises three main areas: pre-IPO, IPO and post-IPO. The corporate finance and capital market services of CCB International have raised over HK$4 trillion from the global equity market for hundreds of companies. 

Founded in 2010, YF Capital is a leading private equity firm in China. YF Capital currently manages multiple USD and RMB funds. The company has formed deep sector expertise and industry insights in our focused sectors, including the internet, technology, healthcare, entertainment, consumer, finance and logistics.